SVF
Insufficient· Insufficient EvidenceNarrative Review

Whispers of Growth: The Impact of MicroRNA on the Proliferation Potential of Adipose-Derived Stem Cells-A Review.

Bahrami M., Abbaszadeh HA., Berjis K., Moradi A.

Narrative Review on Hip, published in Biomed Res Int (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biomed Res Int (2026)
Country
United States
Reported sample size
—
PMID
41623687
DOI
10.1155/bmri/4137354

Abstract (original English)

Adipose-derived stem cells (ADSCs) have garnered significant interest in regenerative medicine (RM) due to their abundant availability, ease of isolation, and ability to differentiate into various cell types. The growth of ADSCs is crucial for their therapeutic effectiveness, as it directly influences their ability to repair damaged tissues. MicroRNAs (miRNAs) are recognized as powerful regulators of gene expression and cellular functions, including proliferation, and are believed to play a role in modulating the proliferative potential (PP) of ADSCs. This review is aimed at exploring existing research on how miRNAs influence the PP of ADSCs, focusing on aspects such as the cell cycle, ADSC factors, and various signaling pathways, including STAT3, PI3K-AKT, Hippo, Notch, Wnt/ β -catenin, and MAPK pathways that affect ADSC proliferation. We also examined the impact of miRNAs on the migration of ADSCs. Through a review of relevant studies, we identified several miRNAs that influence the PP of ADSCs through various mechanisms. These miRNAs interact with key signaling pathways, cell cycle regulators, and other elements related to cell proliferation, leading to both positive and negative effects on ADSC growth. Additionally, numerous studies have suggested that modifying miRNA expression levels could enhance the PP of ADSCs for therapeutic applications. This review provides valuable

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
MicroRNAsHumansCell ProliferationStem CellsAdipose TissueSignal TransductionAnimalsCell Differentiation
Hip
View on PubMedDOI

Related research